Overall the company’s sales increased 9.1 percent over the same period last year and net earnings reached $4.3 billion. The growth was primarily due to its new drug Olysio. Here are five key notes on the report, focusing on the company’s orthopedic and spine sales:
1. Johnson & Johnson is still dealing with cost associated with the 2012 acquisition of Synthes. The second quarter results included a charge for after-tax special items of around $400 million, primarily related to litigation accrual as well as integration and transaction costs related to the Synthes pick-up.
2. Second quarter orthopedic sales reached $2.4 billion, a 3.5 percent increase over the same period last year. The company’s orthopedics segments continue as a leader in the worldwide market and DePuy Synthes is realizing revenue and cost savings from integration.
3. International orthopedic sales were $1.1 billion, a 5.8 percent increase over the same period last year. United States orthopedics sales reached $1.2 billion, a 1.6 percent increase over the previous year.
4. At the six months end, worldwide orthopedics sales reached $4.8 billion, a 2.5 percent increase over the same period last year. International sales were $2.3 billion, a 3.1 percent increase, and United States sales were $2.5 billion, a 2 percent increase over the same period last year.
5. DePuy Synthes recently partnered with Tissue Regeneration Systems to develop three-dimensional printing technologies. The agreement allows for potential opportunities in the future for a range of DePuy Synthes applications. The company also released the GLOBAL UNITE Anatomic Shoulder System and CORAIL revision hip system.
More Articles on Medical Devices:
10 Trends in the Global Orthopedic Power Tools Market
Smith & Nephew Drops Auditors Ernst & Young for KPMG
Misonix Spine Device Shows Reduced Blood Loss During Scoliosis Correction
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
